Research Progress of FLT3 Mutation in Acute Myeloid Leukemia --Review / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 922-926, 2023.
Artículo
en Chino
| WPRIM
| ID: wpr-982152
ABSTRACT
Acute myeloid leukemia (AML) is a heterogeneous hematopoietic tumor originated from hematopoietic stem cells. FLT3 is an important receptor tyrosine kinase in cell signal transduction pathway and one of the common mutated genes in AML. AML patients with FLT3-ITD mutation have a poor prognosis and tendency to relapse. Therefore, early identification of FLT3 gene mutation and selection of appropriate treatment are particularly important. Currently, the small moleculetargeted drugs have been new treatment methods for AML patients with FLT3-ITD mutation, but accompanied drug resistance need to be solved. This paper reviews the mechanism of FLT3 mutation, the clinical significance of FLT3 mutation in AML, FLT3 inhibitors and drug resistance mechanism.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Leucemia Mieloide Aguda
/
Transducción de Señal
/
Proteínas Tirosina Quinasas Receptoras
/
Inhibidores de Proteínas Quinasas
/
Tirosina Quinasa 3 Similar a fms
/
Mutación
Límite:
Humanos
Idioma:
Chino
Revista:
Journal of Experimental Hematology
Año:
2023
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS